Location
Tampa Convention Center
333 S Franklin Street
Tampa, FL 33602
Phone: (813) 274-8511
Program Schedule — Eastern Time
11:15 AM – 11:45 AM — Registration and Lunch
11:45 AM – 1:15 PM — Educational Meeting
Meeting Room
Ballroom A – Level 1
This event will also be webcast live. Please see Registration tab for details.
There is no fee to participate in this event. For the in-person symposium in Tampa, preregistration is required as seating is limited.
Faculty David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
The Ohio State University and
The James Cancer Center
Columbus, Ohio
Matthew A Powell, MD
Professor
Department of Obstetrics and Gynecology
Washington University School of Medicine
St Louis, Missouri
Additional faculty to be announced.
Moderator Shannon N Westin, MD, MPH
Professor
Director, Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.
Program Schedule — Eastern Time
11:15 AM – 11:45 AM — Registration and Lunch Buffet
11:45 AM – 1:15 PM — Educational Meeting
MODULE 1: Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Endometrial Cancer
Current indications for MSI/MMR testing in patients with endometrial cancer; available testing platforms
Key efficacy and safety data with dostarlimab for patients with MSI-H/dMMR tumors in the
GARNET trial
Efficacy and safety findings with pembrolizumab monotherapy for patients with previously treated MSI-H/ dMMR advanced endometrial cancer on the KEYNOTE-158 study
Current clinical roles for dostarlimab and pembrolizumab in the treatment of MSI-H/dMMR advanced endometrial cancer; optimal integration into practice
Available clinical trial data with other anti-PD-1/PD-L1 antibodies (eg, durvalumab, atezolizumab) for patients with MSI-H/dMMR endometrial cancer
MODULE 2: Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer
Biologic rationale for combining immune checkpoint inhibitors with VEGF inhibitors for recurrent pMMR endometrial cancer
Key efficacy and safety data with pembrolizumab in combination with lenvatinib for patients with advanced pMMR tumors in the KEYNOTE-775 trial
Antitumor efficacy observed with pembrolizumab/lenvatinib in patients with MSI-H/dMMR endometrial cancer in the KEYNOTE-775 trial; current nonresearch role, if any
Response rates observed with single-agent dostarlimab for patients with recurrent and/or advanced pMMR disease in the GARNET trial
Design, eligibility criteria and key efficacy and safety endpoints for the Phase III LEAP-01 trial comparing pembrolizumab/lenvatinib to chemotherapy as first-line treatment for advanced or recurrent endometrial cancer; estimated completion date
Ongoing Phase III trials evaluating paclitaxel/carboplatin with or without immune checkpoint inhibition for patients with newly diagnosed or recurrent advanced endometrial cancer (eg, RUBY, AtTEnd)
MODULE 3: Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer
Incidence, severity and timing of toxicities associated with pembrolizumab/lenvatinib in patients with endometrial cancer
Appropriate initial dosing and dose-modification strategies with pembrolizumab/lenvatinib; available data exploring the effects of lenvatinib dose reduction on antitumor activity
Similarities and differences in the frequency and type of adverse events associated with pembrolizumab and dostarlimab monotherapy
Appropriate monitoring for and management of immune-mediated toxicities and other adverse events with pembrolizumab or dostarlimab
Role of rechallenge for patients for whom anti-PD-1/PD-L1 antibody therapy has been held as a result of immune-related adverse events
MODULE 4: Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer
Mechanism of action of selinexor and biologic rationale for targeting XPO1 in patients with endometrial cancer
Key efficacy and safety findings from the Phase III SIENDO trial evaluating selinexor as maintenance therapy after first-line chemotherapy for patients with advanced endometrial cancer
Efficacy of selinexor in patients with p53 wild-type disease and plans for development of this drug for endometrial cancer
Biologic rationale for, early-phase data with and ongoing evaluation of PARP inhibitors for endometrial cancer
Design, eligibility criteria and key endpoints of the Phase III DUO-E study of durvalumab and platinum-based chemotherapy followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer; estimated completion date
Early antitumor activity observed with HER2-targeted therapies for HER2-positive endometrial cancer (eg, trastuzumab, trastuzumab/pertuzumab, trastuzumab deruxtecan)
Other novel agents and strategies under evaluation for the treatment of advanced endometrial cancer
Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Evaluate the importance of microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiency assessment for patients with endometrial cancer, and adapt current testing practices to optimally identify genetic abnormalities.
Review the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or MMR-deficient endometrial cancer, and appropriately integrate these agents into the care of patients with relapsed/refractory disease.
Recognize the biologic rationale for and available data with the combination of anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel approach.
Design and implement a plan of care to manage side effects and toxicities associated with immune checkpoint inhibitor-based therapies for endometrial cancer in order to support quality of life and continuation of therapy.
Describe the scientific justification for, published research data with and toxicity profiles of novel agents and strategies under investigation for endometrial cancer, and effectively prioritize clinical trial opportunities for eligible patients.
CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.
Tampa Convention Center
333 S Franklin Street
Tampa, FL 33602
Phone: (813) 274-8511
Meeting Room
Ballroom A – Level 1
Directions
The Tampa Convention Center is the main venue for the SGO Annual Meeting on Women’s Cancer.
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.
There is no fee to participate in this event. For the in-person symposium in Tampa, preregistration is required as seating is limited.
IN-PERSON registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
